User login
Key clinical point: Women with MS may be able to have children, breastfeed, and resume treatment without experiencing an increased risk of relapse during the postpartum period.
Major finding: Patients’ annualized relapse rate was 0.39 pre-pregnancy, 0.07-0.14 during pregnancy, 0.27 in the first 3 months postpartum, and 0.37 at 4-6 months postpartum.
Study details: An analysis of prospectively collected data from 466 pregnancies among 375 women with MS between 2008 and 2016.
Disclosures: The study was supported by the National Multiple Sclerosis Society. The researchers had no disclosures.
Citation: Langer-Gould A et al. AAN 2019, Abstract S6.007.
Key clinical point: Women with MS may be able to have children, breastfeed, and resume treatment without experiencing an increased risk of relapse during the postpartum period.
Major finding: Patients’ annualized relapse rate was 0.39 pre-pregnancy, 0.07-0.14 during pregnancy, 0.27 in the first 3 months postpartum, and 0.37 at 4-6 months postpartum.
Study details: An analysis of prospectively collected data from 466 pregnancies among 375 women with MS between 2008 and 2016.
Disclosures: The study was supported by the National Multiple Sclerosis Society. The researchers had no disclosures.
Citation: Langer-Gould A et al. AAN 2019, Abstract S6.007.
Key clinical point: Women with MS may be able to have children, breastfeed, and resume treatment without experiencing an increased risk of relapse during the postpartum period.
Major finding: Patients’ annualized relapse rate was 0.39 pre-pregnancy, 0.07-0.14 during pregnancy, 0.27 in the first 3 months postpartum, and 0.37 at 4-6 months postpartum.
Study details: An analysis of prospectively collected data from 466 pregnancies among 375 women with MS between 2008 and 2016.
Disclosures: The study was supported by the National Multiple Sclerosis Society. The researchers had no disclosures.
Citation: Langer-Gould A et al. AAN 2019, Abstract S6.007.